Tandem Diabetes Care’s first quarter results were met with a positive market reaction, reflecting the company’s ability to exceed Wall Street’s revenue and GAAP loss expectations. Management pointed to the successful ramp of new product launches, the initial rollout of its pay-as-you-go (PayGo) pharmacy model, and early international direct channel expansion as key drivers. CEO John F. Sheridan emphasized, “We are bringing a great deal of new technology and business model changes that we believe will really help us grow new starts from MDI [multiple daily injection] patients.” The quarter also saw improvements in operational efficiency, supported by cost discipline and enhanced sales infrastructure.
Is now the time to buy TNDM? Find out in our full research report (it’s free for active Edge members).
Tandem Diabetes (TNDM) Q1 CY2026 Highlights:
- Revenue: $247.2 million vs analyst estimates of $239.6 million (5.5% year-on-year growth, 3.2% beat)
- Adjusted EPS: -$0.30 vs analyst estimates of -$0.44 (32.1% beat)
- Adjusted EBITDA: $2.73 million (1.1% margin, 103% year-on-year growth)
- The company reconfirmed its revenue guidance for the full year of $1.08 billion at the midpoint
- Operating Margin: -7.1%, up from -51.6% in the same quarter last year
- Market Capitalization: $966.9 million
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Tandem Diabetes’s Q1 Earnings Call
- Matthew Stephan Miksic (Barclays) asked about drivers of quarterly growth—including type 2 adoption, pharmacy uptake, and sensor integration. CEO John F. Sheridan said growth was “a little bit of all of the above,” with new technologies and business model changes supporting broader momentum.
- Christopher Thomas Pasquale (Nephron Research) probed the international segment’s revenue growth despite lower shipment volumes, inquiring about one-time items. CFO Leigh A. Vosseller explained that favorable currency and a one-time Swiss accounting benefit offset some expected headwinds from the direct channel transition.
- Michael Holden Kratky (Leerink Partners) questioned the dip in pharmacy channel sales mix and the pathway to full-year targets. Vosseller emphasized the early-stage nature of the transition, highlighting rapid increases in formulary coverage and ongoing process improvements as key to scaling pharmacy fulfillment.
- Richard Samuel Newitter (Truist Securities) asked about infusion set shortages and their financial impact. Sheridan described the issue as significant for affected patients but modest in aggregate, with ongoing mitigation efforts and expectations for gradual improvement later in the year.
- Joanne Karen Wuensch (Citi) sought guidance on the Mobi Tubeless launch timing and commercialization approach. Sheridan outlined a phased launch—starting with small groups post-clearance—aimed at ensuring a smooth ramp and minimizing disruption to existing sales patterns.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will be monitoring (1) the pace of PayGo pharmacy channel adoption and its impact on recurring supply revenue, (2) the resolution of infusion set supply constraints and resulting effects on sales growth, and (3) the regulatory progress and early feedback for Mobi Tubeless and international direct channel expansion. Advances in CGM integration and coverage for type 2 diabetes patients will also be important indicators for sustained momentum.
Tandem Diabetes currently trades at $14.34, down from $18.47 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
